Garage Brain Science Co., Ltd.
Update：2026/11/10
Industries
Main Industry
Biotechnology
Main Product/Service
Preventive healthcare platform featuring AI Dr. Listening™, small-molecule protein structure repair drug Reprofold®, rapid misfolded protein screening FoldCheck™, and misfolded protein detection systems HIMP™ and eHIMP™.
The content above was translated by Ai
Founded Year
2023
Unified Business No.
89172624
Status
Active
Number of Employees
8
Total Paid-in
Capital
17,536,700 (NT$)
Location of Company
Taiwan
, Taichung City
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Garage Brain Science Co pioneered the “pre-symptomatic treatment platform,” combining AI-driven molecular diagnostics with protein structure repair therapies to prevent chronic diseases such as dementia and diabetes. Founded by scientists who discovered the link between protein misfolding and neurodegeneration, the company has developed proprietary technologies that integrate early detection, patient stratification, and preventive intervention. The diagnostic platform requires only 50 μL of blood and delivers misfolded protein detection in 3 hours with 92–98% accuracy, already aiding multinational pharmaceutical companies in expanding early-stage clinical trial populations. Its core drug, Reprofold®, can repair multiple misfolded proteins, with animal studies showing a 40% lifespan extension and potential across multiple disease treatments. Coupled with AI tools Dr. Listening™ and Disease Origin Finder™, GBS enables precise patient stratification and personalized prevention. The company is advancing U.S. clinical programs and collaborations, targeting the $300 billion preventive healthcare market.
The content above was translated by Ai
